XML 52 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2014
Jan. 01, 2018
Dec. 31, 2017
Revenue          
Accumulated Deficit $ (929,388)       $ (812,517)
Accounts receivable 4,020       $ 1,880
Revenue recognized from contract liabilities 600        
Revenues 4,068 $ 1,534      
ASU 2014-09          
Revenue          
Accumulated Deficit       $ (1,300)  
Deferred revenue       (800)  
Accounts receivable       $ 500  
Product Development and Licensing Agreements          
Revenue          
Revenues 992 556      
Contracts and Grants          
Revenue          
Revenues 3,076 978      
Bristol-Myers Squibb Company | Product Development and Licensing Agreements          
Revenue          
Deferred revenue     $ 5,000    
Reimbursement of external costs (as percent)     50.00%    
Revenues 900        
IAVI & Frontier | Contracts and Grants          
Revenue          
Revenues 2,300 0      
Rockefeller | Contracts and Grants          
Revenue          
Revenues $ 700 $ 800